How would you summarize your study for a lay audience? Previous research indicates that mast cells, a type of immune cell found in the tissues throughout the body, cause inflammation during an asthma ...
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024 Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in ...
Webinar to be held Tuesday, December 2nd, at 8:00 am ETREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper ...
REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
A new study by researchers at Brigham and Women’s Hospital reveals the mechanisms behind severe inflammation in asthma. The findings demonstrate that prostaglandin E2 (PGE2), a naturally occurring ...
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
InvestorsHub on MSN
Jasper Shares Surge Following Encouraging Early Asthma Trial Data
Jasper Therapeutics Inc. (NASDAQ:JSPR) jumped 17.4% in premarket trading Tuesday after the company released promising initial ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Jasper also announces ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback